Sugi Predict

Sugi Predict / Compounds / SCHEMBL4420088

SCHEMBL4420088

SCHEMBL4420088

Cc1cc(O)cc2c1C(O)C(c1ccc(O)cc1)=C2c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 11/20 0.44
▸ ESR1 P03372 11/20 0.43
▸ MMP3 P08254 1/20 0.38
▸ BCL2L1 Q07817 1/20 0.38
▸ BACE1 P56817 1/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ ABCB1 P08183 1/20 0.36
▸ BCR P11274 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ ALOX5 P09917 1/20 0.33
▸ NTSR1 P30989 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ MPI P34949 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4430572 0.70 ESR2 (0.73) ESR2ESR1BACE1ALDH1A1MAPT
SCHEMBL4424188 0.69 ESR2 (0.55) ESR2ESR1MMP3BCL2L1BACE1
SCHEMBL4423205 0.68 ESR1 (0.57) ESR2ESR1MMP3BCL2L1
SCHEMBL4423382 0.66 ALDH1A1 (0.45) ESR2ESR1MMP3BCL2L1ABL1
SCHEMBL1089399 0.65 LMNA (0.43) MMP3BCL2L1BACE1ALDH1A1MEN1
SCHEMBL30693664 0.65 ESR2 (0.62) ESR2ESR1BCL2L1BACE1ABL1
SCHEMBL2861284 0.65 ESR2 (0.62) ESR2BCL2L1BACE1ABL1ABCB1
SCHEMBL8337717 0.65 ESR2 (0.62) ESR2MMP3BCL2L1BACE1ABL1
O-Xylene SCHEMBL27949585 0.63 MMP3 (0.75) ESR2ESR1MMP3BCL2L1ABL1
SCHEMBL23940773 0.63 ESR2 (0.60) ESR2ESR1BCL2L1BACE1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090326018-A1 2-Phenyl indene derivatives useful as estrogen receptor ligands KARO BIO AB (SE) 2009-12-31 — — US claimed
US-20090326018-A1 2-Phenyl indene derivatives useful as estrogen receptor ligands KARO BIO AB (SE) 2009-12-31 — — US disclosed
US-20090326018-A1 2-Phenyl indene derivatives useful as estrogen receptor ligands KARO BIO AB (SE) 2009-12-31 — — US disclosed
US-20090326018-A1 2-Phenyl indene derivatives useful as estrogen receptor ligands KARO BIO AB (SE) 2009-12-31 — — US disclosed
EP-2074102-A1 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2009-07-01 — — EP disclosed
WO-2008043567-A1 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2008-04-17 — — WO disclosed
WO-2008043567-A1 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2008-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326018-A1 2-Phenyl indene derivatives useful as estrogen receptor ligands ESR1, GPER1, ESR2 ESR2 3/4885ESR1 1/4885MMP3 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.